Ionpath + press release
Web1 jan. 2024 · Ionpath® is a registered trademark and MIBI™ & MIBIscope™ are trademarks of Ionpath, Inc. For Research Use Only. Not for use in diagnostic procedures. Contact … Web24 sep. 2024 · MENLO PARK, Calif., Sept. 24, 2024 /PRNewswire/ -- IONpath, Inc., the leader in high-definition spatial proteomics, today announced the close of a $18 million Series B financing led by Samsara...
Ionpath + press release
Did you know?
WebMIBI™ technology (Multiplexed Ion Beam Imaging) uses Secondary-Ion Mass Spectrometry (SIMS), a type of mass spectrometry traditionally used in the semiconductor industry, to image antibodies tagged with monoisotopic metal reporters. This unique technology enables: Visualization of 40+ markers simultaneously. Imaging at the sub … WebMultiplexed Ion Beam Imaging (MIBI™) technology from Ionpath enables high-definition spatial proteomics that uniquely provides actionable analysis of the tissue microenvironment—delivering novel insights into disease …
Web24 sep. 2024 · MENLO PARK, Calif., Sept. 24, 2024 /PRNewswire/ -- IONpath, Inc., the leader in high-definition spatial proteomics, today announced the close of a $18 million … Web15 feb. 2024 · Accomplished executive and scientist will lead company into next phase of commercial growth MENLO PARK, Calif. — IONpath, Inc., the leader in high-definition spatial proteomics, today announced the appointment of Sander Gubbens, PhD, as its new CEO. Dr. Gubbens was most recently President of Gatan, which revolutionized the field …
WebIonpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis. Web10 sep. 2024 · (2024-09-10 NDAQ:LAB) Fluidigm Files Patent Infringement Suit Against IONpath (2024-09-10 NDAQ:LAB) Fluidigm Files Patent Infringement Suit Against …
Web11 feb. 2024 · MENLO PARK, California, Feb. 11, 2024 /PRNewswire/ — IONpath, Inc., today announces the launch of a dedicated service business providing access to their proprietary MIBIscope™ multiplexed imaging platform and its team of experts to support pharmaceutical and biotechnology companies working in immuno-oncology. IONpath …
Web10 mei 2024 · IonPath, Inc. announced that it will issue 70,531,242 voting series C preferred shares at a price of $1.0455 per share for the gross proceeds of … simple business casual menWeb11 mei 2024 · On May 11, 2024, IonPath, Inc. closed the transaction. The transaction included participation from new investor, Thermo Fisher Scientific Inc.... Advanced search ... Press Releases. Security Transactions. Earnings reports. New markets. New products. Corporate strategies. Legal risks. Share buybacks. Mergers and acquisitions. Call ... simple business checksravi singh and ana brettWeb5 nov. 2024 · MIBIscope allows researchers to visualize over 40 biomarkers simultaneously with high resolution, sensitivity, and throughput, and is compatible with standard tissue processing techniques Menlo Park, Calif. – IONpath, Inc., a company revolutionizing multiplexed tissue imaging, launched the MIBIscope™ System, the first commercially … simple business checking account onlineWebIonpath General Information Description Developer of an ion beam imaging technology designed to offer tissue imaging and analysis to accelerate discovery and improve … ravis in frenchWebThe MIBIscope enables over 40 markers to be visualized simultaneously with single step staining and single step imaging. MIBIscope images from a 3mm x 3mm scan of a granulomatous lung section from a Mycoplasm tuberculosis infected patient. The image to the left shows immune infiltrate in the infected tissue (CD45, yellow; CD31, red; SMA, … simple business casual wardrobeWeb11 mei 2024 · MENLO PARK, Calif. — Ionpath, Inc., a leader in high-definition spatial proteomics, today announced that Thermo Fisher Scientific, the world leader in serving … ravis hyderabad house menu